Fennec Pharmaceuticals Inc. (FRX) Insider S.P.A. Essetifin Purchases 294,115 Shares of Stock
Fennec Pharmaceuticals Inc. (TSE:FRX) insider S.P.A. Essetifin purchased 294,115 shares of the stock in a transaction dated Tuesday, December 12th. The stock was acquired at an average cost of C$8.50 per share, with a total value of C$2,499,977.50.
Fennec Pharmaceuticals Inc. (TSE FRX) traded up C$0.28 during trading hours on Thursday, reaching C$11.68. 2,425 shares of the company were exchanged, compared to its average volume of 4,580. Fennec Pharmaceuticals Inc. has a 12 month low of C$2.30 and a 12 month high of C$16.23.
Separately, Laidlaw initiated coverage on shares of Fennec Pharmaceuticals in a research report on Wednesday, November 29th. They issued a “buy” rating and a C$22.00 price target for the company.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.